upcoming Phase 3 trials evaluating Buntanetap in Parkinson's disease

[Farooqji]

irpages2.eqs.com/websites/a...

[Bolt_Upright]

"Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs) currently being developed for Alzheimer's disease (AD) and PD. In Phase 2a trials, Buntanetap was shown to be well-tolerated and safe, and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were met as Buntanetap treatment resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients and in a reduction of the spinal fluid markers. "

[Canddy]

Thanks, Farooqji this study (Phase 3) probably will not read out until early 2024 but fingers crossed that it works!

[Canddy in reply to Canddy]

I meant to say at the earliest it won't read out until early 2024

[Hidden]

healthunlocked.com/cure-par...